Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that a significantly higher proportion of patients with newly diagnosed chronic myeloid leukemia who were treated with bosutinib (39 percent) experienced a major molecular response (MMR), a secondary endpoint, compared with patients treated with imatinib (26 percent) in the intent-to-treat (ITT) population (p=0.002).
Public believe China and India set to become World leaders for innovation
- Details
- Category: AstraZeneca
China is set to become the world's powerhouse of innovation over the next decade, eclipsing the United States and Japan, according to an international survey released by AstraZeneca. The world's most populous nation and second largest economy will also be its most inventive by 2020, followed by India, the AstraZeneca Innovation Survey shows.
Rituxan/MabThera decreased the risk of needing later treatment with chemotherapy or radiotherapy by 80%
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive data from a Phase III study of Rituxan/MabThera (rituximab) in patients with advanced follicular lymphoma who did not have symptoms of disease (asymptomatic disease).
Amgen's Nplate(R) Maintains Platelet Counts for More Than Five Years in Adults with Chronic ITP
- Details
- Category: Amgen
Amgen Inc. (Nasdaq: AMGN) announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate(R) (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Commitment of Novartis in advancing treatments for patients with cancer and rare diseases
- Details
- Category: Novartis
With more than 170 presentations focused on its marketed and pipeline compounds at key oncology medical congresses in December, Novartis continues to demonstrate progress of its innovative research and development efforts, collaboration with the scientific community and commitment to patients with cancer and rare diseases[1],[2].
Genzyme Completes Sale of Genetic Testing Business to LabCorp
- Details
- Category: Genzyme
Genzyme Corporation (Nasdaq: GENZ) has completed the sale of Genzyme Genetics to Laboratory Corporation of America Holdings (NYSE: LH) for $925 million in cash. Under the final terms of the agreement, LabCorp purchased substantially all of the assets of the Genzyme Genetics business, including testing services, technology,
Bristol-Myers Squibb and Alvin Ailey American Dance Theater Announce First-of-Its-Kind Collaboration
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Alvin Ailey American Dance Theater announced the launch of the 2011 REYATAZ® (atazanavir sulfate) "Fight HIV Your Way" contest. The contest aims to help raise awareness about HIV/AIDS among the general public and inspire people impacted by the disease to continue their fight.
More Pharma News ...
- GlaxoSmithKline to increase its shareholding in Theravance
- GlaxoSmithKline and JSC Binnopharm enter vaccine production alliance in Russia
- Merck KGaA Announces Extension of FDA Priority Review Period for Cladribine Tablets
- Abbott Named One of the Top 10 Companies in Calvert Diversity Survey
- Roche obtains license for EGFR lung cancer assays and will develop Tarceva companion diagnostic test
- Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye
- Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease